6671-85-8Relevant articles and documents
DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS
-
Paragraph 0177; 0290, (2018/03/28)
Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
Reactivity and selectivity in hydrovinylation of strained alkenes
Liu, Wang,Rajanbabu
experimental part, p. 7636 - 7643 (2010/12/29)
The scope of Ni(II)-catalyzed hydrovinylation has been extended to strained alkenes such as heterobicyclic [2.2.1]heptanes and cylobutenes. Reactions involving the heterobicyclic compounds are rare examples for this class of compounds where the metal-catalyzed C-C bond-forming reactions proceed without a concomitant ring-opening process. While the enantioselectivity in these systems remains modest, hydrovinylation of endo-5,6 - bis-benzyloxymethylbicyclo[2.2.1] hept-2-ene gives excellent yield (>90%) of the product with one of the highest enantioselectivities (95-99% ee) reported for a C-C bond-forming reaction of norbornenes.
BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS
-
Page/Page column 29; 30, (2008/06/13)
The present invention is directed to bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. T